Boston Scientific: Paging the Doctor: Watchman (Part II)

Research evidence excerpt

Boston Scientific: Paging the Doctor: Watchman (Part II)

Accessible version

Boston Scientific

Paging the Doctor: Watchman (Part II)

Maintain Rating: BUY | PO: 68.00 USD | Price: 48.34 USD

We spoke with an IC implanting standalone LAAC 11 June 2026

We spoke with an Interventional Cardiologist who is a key opinion leader in the LAAC Equity

space as the Chair of the 2025 SCAI/HRS LAAO Guidelines and the Chair of the national

LAAO Registry. He did 120 cases (mostly standalone) in 2025 and expects the number to Travis Steed Research Analyst

grow to 130 in 2026. He expects his institution’s total volume (350 cases in 2025) to BofAS

grow 5-10% this year as well. He was not aware the LAAC market had slowed and +1travis.steed@bofa.com404 607 3251

seemed surprised when we told him what has happened in the market. We spoke to a Stephanie Elghazi

different doc on Watchman (LAAC device) (See note Watchman doc check) and built a Research Analyst

BofAS

new Watchman model to better estimate when it stabilizes (see note Watchman model). +1 646 855 4568

stephanie.elghazi@bofa.com

Doc is not seeing standalone referral slowdown Enjia Cao

Research Analyst

The doc says he has enough patients but lacks room on the schedule. New patients BofAS

today need to wait until September for a procedure. Referrals continue to grow with no +1 646 743 9861

enjia.cao@bofa.com

recent changes in trend. On potential reasons for a slowdown in the broader Watchman

Gracia Mahoney

market, he points to capacity issues. More appendage occlusion means fewer TAVRs, Research Analyst

coronary cases, or other structural heart procedures. But the doc said that he doesn’t BofAS +1 646 855 1136

see any meaningful inflection in other procedures crowding out his own LAAC volumes. gracia.mahoney@bofa.com

Aidan Lahey